Affimed Stock Price, News & Analysis

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, announces upcoming presentations at investor conferences in February 2022. Key events include the SVB Leerink 2022 Global Healthcare Conference on February 16, 2022, at 11:20 a.m. EST, and Citi’s Virtual Immuno-Oncology Summit on February 17, 2022, at 2:30 p.m. EST. Both presentations will be available via webcast. The company aims to leverage its ROCK® platform for innovative tumor-targeted therapies, focusing on harnessing innate immune responses to fight various cancers.

Affimed N.V. (Nasdaq: AFMD) announced the completion of enrollment in its REDIRECT study (AFM13-202) aimed at evaluating AFM13 for relapsed or refractory CD30-positive T-cell lymphoma, with topline results expected in 2H 2022. The FDA approved a protocol amendment allowing 40 patient enrollments at the highest dose in a related trial. The company has launched a broad development strategy for AFM24, targeting EGFR-expressing tumors, and plans to initiate a first-in-human study for AFM28 in late 2022. Affimed's cash reserves are projected to sustain operations into 2H 2023.

Affimed N.V. (Nasdaq: AFMD) announced that CEO Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 10:30 a.m. EST. The event will showcase Affimed's commitment to immuno-oncology and its innovative ROCK® platform for cancer treatment. A live webcast of the presentation will be available on Affimed’s website and can be accessed for 30 days post-event. For further inquiries or to schedule meetings, contact Alex Fudukidis, the Director of Investor Relations.

Affimed (Nasdaq: AFMD) revealed promising preclinical data on its Innate Cell Engager (ICE®) programs, AFM28 and AFM13, at the ASH Annual Meeting. AFM28 showed significant effectiveness in targeting CD123+ cells in acute myeloid leukemia and myelodysplastic syndrome, with a potent NK cell activation and low risk of cytokine release syndrome. Additionally, AFM13 demonstrated its potential as an off-the-shelf product with retained efficacy post-cryopreservation. Both advancements highlight Affimed's commitment to enhancing cancer treatments through innovative immunotherapy approaches.

Affimed N.V. (Nasdaq: AFMD) announced promising results from a clinical study investigating AFM13 for CD30-positive lymphoma. In a trial involving 19 patients, the overall response rate reached 89.5%, with a 36.8% complete response rate. Patients treated at the recommended phase 2 dose showed a remarkable 100% response after one cycle, with a 38.5% complete response rate. The treatment demonstrated a favorable safety profile, with minimal adverse effects reported. The company plans to present complete results at future conferences, indicating significant advancements in addressing challenging lymphomas.

Affimed N.V. (Nasdaq: AFMD) has commenced patient recruitment for a phase 1/2a study focusing on the innate cell engager (ICE®) AFM24 combined with Roche’s atezolizumab, targeting solid tumors. This trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combination. AFM24 engages natural killer cells to enhance anti-tumor activity. The study involves patients with various solid tumors who have undergone prior treatments. Preclinical data suggests a favorable safety profile and anti-tumor efficacy, emphasizing the potential of this novel therapy.

Affimed N.V. (Nasdaq: AFMD) announced positive interim results from a phase 1-2 study, showing a 100% objective response rate in patients with CD30-positive relapsed or refractory lymphomas after one treatment cycle involving the pre-complexed cbNK cells with their innate cell engager AFM13. Of 12 patients treated at the recommended phase 2 dose, 42% achieved a complete response, with no serious adverse events reported. A virtual investor event is scheduled for December 9 to discuss these findings further.

Affimed N.V. (Nasdaq: AFMD) announced the presentation of preclinical data on its innate cell engagers (ICE®) AFM13 and AFM24 at the SITC Annual Meeting. The findings, derived from a collaboration with Karolinska Institutet, demonstrate enhanced NK cell activity and macrophage involvement in tumor cell killing. AFM24's ability to induce antibody-dependent cellular phagocytosis (ADCP) was highlighted, enhancing potential anti-tumor effects across various tumor types. AFM24 is currently in Phase 1/2a trials for EGFR-expressing solid tumors, with additional studies planned with an anti-PD-L1 checkpoint inhibitor.

Affimed N.V. (Nasdaq: AFMD) reported its third quarter 2021 financial results, highlighting a net loss of €17.1 million or €0.14 per share, worsening from a net loss of €6.0 million in Q3 2020. Cash and cash equivalents increased to €198.7 million, projected to sustain operations into the second half of 2023. Significant clinical updates include ongoing patient recruitment for the AFM13 and AFM24 trials. Both candidates are expected to generate multiple catalysts, with AFM24's expansion phase set to start by year-end 2021.